2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 72

Longitudinal Expression of CXCL10 in Psoriasis Patients That Develop Psoriatic Arthritis
Abstract Number: 73

Dysregulation of Hypomethylated Age-Related CpG Sites Characterize T-Cells and Monocytes from Treatment Naive Rheumatoid Arthritis Subjects
Abstract Number: 74

Arthritis-Associated DNA Hypermethylation Provokes Increased Antibody Expression in Mouse Model of Rheumatoid Arthritis
Abstract Number: 75

Genetic Analysis of Urate Transporters ABCG2, SLC17A3, SLC22A11 and SLC17A1 in Primary Hyperuricemia and Gout
Abstract Number: 76

Chromatin Interactions Reveal Novel Gene Targets for Drug Repositioning in Rheumatic Diseases
Abstract Number: 77

Integrated Analysis of Microrna and mRNA Expression Profiles Related to Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome Patients
Abstract Number: 78

Whole Blood Gene Modules Show Differences Between Active Lupus Nephritis and Quiescent Disease As Well As Absence of Plasmablast Signature in This Adult Population
Abstract Number: 79

A NOVEL Missense Mvk mutation in a Family with Familial Mediterranean Fever-like Disease
Abstract Number: 80

Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
Abstract Number: 81

Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey
Abstract Number: 82

Patients with Rheumatoid Arthritis in Germany: Are They Ready for Ehealth Via Mobile Medical Applications?
Abstract Number: 83

A Qualitative Study Exploring Participants’ Perception of the Making It Work Program, an Online Program to Help People with Inflammatory Arthritis Maintain Employment
Abstract Number: 84

Treatment Outcomes and Predictors of Patient Support Program Use Among Patients with Rheumatoid Arthritis: Results from a Post-Marketing Observational Study (PMOS)
Abstract Number: 85

Evaluation of Patient Satisfaction with the on-Tracc Program; Benefits of a Joint Approach
Abstract Number: 86

Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture

« Previous Page
1
…
5
6
7
8
9
…
219
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].